Last edition
News about "Revolution Medicines"
Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib
Revolution Medicines presented phase 1/2 clinical data showing the potential of zoldonrasib combination regimens in patients with RAS G12D metastatic pancreatic cancer at ESMO Gastrointestinal Cancers Congress 2026.
Revolution Medicines | 04/07/2026 | By News Bureau
US Food and Drug Administration Clears Expanded Access Pathway for Daraxonrasib
Regulator issues “safe to proceed” letter to Revolution Medicines, enabling early patient access to investigational therapy for advanced pancreatic cancer.
Revolution Medicines | 04/05/2026 | By News Bureau | 349
Breakthru Medicine Raises USD 60 Million Series A to Advance Cancer Drugs
Founded by biotech veterans Steve Potts, Mark Mulvihill and Brian Barnett, Breakthru Medicine has raised USD 60 million in Series A funding to advance its stealth oncology pipeline, including molecular glues, small molecules and novel ADC payloads.
Revolution Medicines | 02/02/2026 | By News Bureau | 206
Merck Ends Acquisition Talks With Revolution Medicines
Merck has ended discussions to acquire cancer drug developer Revolution Medicines after the two sides failed to agree on valuation, according to reports. The talks, which had been ongoing for several weeks, were discontinued as differences over pricing could not be resolved.
Revolution Medicines | 27/01/2026 | By Darshana | 138
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy